BRCA1 involvement in toxicological responses and human cancer etiology

Toxicology Letters

Volumn 188, Issue 2, 2009, Pages 77-83

  Georgakilas, Alexandros G ^a   Aziz, Khaled ^a   Ziech, Dominique ^b   Georgakila, Stavroula ^a   Panayiotidis, Mihalis I ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

BRCA1; Cancer; DNA methylation; DNA repair; Oxidative stress; Radiation

Indexed keywords

BRCA1 PROTEIN;

BLADDER CANCER; BREAST CARCINOMA; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; COLORECTAL CARCINOMA; ENVIRONMENT; GENE; GENETIC LINKAGE; HUMAN; INTROSPECTION; LEUKEMIA; LIVER CARCINOMA; LUNG CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEFECT; PROTEIN FUNCTION; REVIEW; STRESS; TOXICOLOGY;

BRCA1 PROTEIN; BREAST NEOPLASMS; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; OXIDATIVE STRESS;

EID: 65549114030     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.04.006     Document Type: Review

References (110)

1. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 (2003) 1117-1130
2. Ashworth A. Drug resistance caused by reversion mutation. Cancer Res. 68 (2008) 10021-10023
3. Auckley D.H., Crowell R.E., Heaphy E.R., Stidley C.A., Lechner J.F., Gilliland F.D., and Belinsky S.A. Reduced DNA-dependent protein kinase activity is associated with lung cancer. Carcinogenesis 22 (2001) 723-727
4. Bae I., Fan S., Meng Q., Rih J.K., Kim H.J., Kang H.J., Xu J., Goldberg I.D., Jaiswal A.K., and Rosen E.M. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 64 (2004) 7893-7909
5. Baldassarre G., Battista S., Belletti B., Thakur S., Pentimalli F., Trapasso F., Fedele M., Pierantoni G., Croce C.M., and Fusco A. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell. Biol. 23 (2003) 2225-2238
6. Baldwin R.L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., and Karlan B.Y. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60 (2000) 5329-5333
7. Beneden R.J.V. Environmental effects and aquatic organisms: investigation of molecular mechanisms of carcinogenesis. Environ. Health Perspect. 105 (1997) 669-674
8. Benhamou S., and Sarasin A. Variability in nucleotide excision repair and cancer risk: a review. Mutat. Res./Rev. Mutat. Res. 462 (2000) 149-158
9. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., and Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275 (2000) 23899-23903
10. Bianco T., Chenevix-Trench G., Walsh D.C.A., Cooper J.E., and Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21 (2000) 147-151
11. Birgisdottir V., Stefansson O., Bodvarsdottir S., Hilmarsdottir H., Jonasson J., and Eyfjord J. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 8 (2006) R38
12. Blaisdell J.O., and Wallace S. Abortive base-excision repair of radiation-induced clustered DNA lesions in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7426-7430
13. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349 (1997) 1505-1510
14. Burma S., Chen B.P.C., and Chen D.J. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair 5 (2006) 1042-1048
15. Cao L., Xu X., Cao L.L., Wang R.-H., Coumoul X., Kim S.S., and Deng C.-X. Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach. Carcinogenesis 28 (2007) 1401-1407
16. Castilla J.H., Couch F.J., Erdos M.R., Haskins K.F., Calzone K., Garber J.E., et al. Mutations in the BRCA1 gene in families with early onset breast and ovarian cancer. Nat. Genet. 8 (1994) 387-391
17. Catteau A., and Morris J.R. BRCA1 methylation: a significant role in tumour development?. Semin. Cancer Biol. 12 (2002) 359-371
18. Chacko P., Rajan B., Joseph B., Mathew B.S., and Pillai M.R. Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res. Treat. 89 (2005) 15-21
19. Chadwick B., and Lane T. BRCA1 associates with the inactive X chromosome in late S-phase, coupled with transient H2AX phosphorylation. Chromosoma 114 (2005) 432-439
20. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. Br. Med. Bull. (2009) ldp005
21. Chen Y., Toland A.E., McLennan J., Fridlyand J., Crawford B., Costello D.J.F., and Ziegler J.L. Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. Genet. Test. 10 (2006) 281-284
22. De Bont R., and van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19 (2004) 169-185
23. Deng C.-X. Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. Mutat. Res./Fundam. Mol. Mech. Mutagen. 477 (2001) 183-189
24. Deng C.-X., and Wang R.-H. Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum. Mol. Genet. 12 (2003) R113-R123
25. Deng C.X., and Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 19 (2000) 1059-1064
26. Ding S.L., Sheu L.F., Yu J.C., Yang T.L., Chen B.F., Leu F.J., and Shen C.Y. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br. J. Cancer 90 (2004) 1995-2001
27. Djuric Z., Everett C.K., and Luongo D.A. Toxicity, single-strand breaks, and 5-hydroxymethyl-2′-deoxyuridine formation in human breast epithelial cells treated with hydrogen peroxide. Free Radic. Biol. Med. 14 (1993) 541-547
28. Easton D.F., Bishop D.T., Ford D., Crockford G.P., and Consortium T.B.C.L. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am. J. Hum. Genet. 52 (1992) 678-701
29. Ellsworth D.L., Ellsworth R.E., Liebman M.N., Hooke J.A., and Shriver C.D. Genomic instability in histologically normal breast tissues: implication for carcinogenesis. Lancet 5 (2004) 753-758
30. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., and Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92 (2000) 564-569
31. Fan R., Kumaravel T.S., Jalali F., Marrano P., Squire J.A., and Bristow R.G. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res. 64 (2001) 8526-8533
32. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
33. Ferrone C.R., Levine D.A., Tang L.H., Allen P.J., Jarnagin W., Brennan M.F., Offit K., and Robson M.E. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J. Clin. Oncol. 27 (2009) 433-438
34. Francisco D.C., Peddi P., Hair J.M., Flood B.A., Cecil A.M., Kalogerinis P.T., Sigounas G., and Georgakilas A.G. Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and non-malignant MCF-10A cells. Free Radic. Biol. Med. 44 (2008) 558-569
35. Franco R., Schoneveld O., Georgakilas A.G., and Panayiotidis M.I. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 266 (2008) 6-12
36. Friedman L.S., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., and King M.C. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 8 (1994) 399-494
37. Fu Y.P., Yu J.C., Cheng T.C., Lou M.A., Hsu G.C., Wu C.Y., Chen S.T., Wu H.S., Wu P.E., and Shen C.Y. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 63 (2003) 2440-2446
38. Futreal P.A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L.M., Haugen-Strano A., Swensen J., Miki Y., Eddington K., McClure M., Frye C., Weaver-Feldhaus J., Ding W., Gholami Z., Soderkvist P., Terry L., Jhanwar S., Berchuck A., Inglehart J.D., Marks J., Ballinger D.G., Barrett J.C., Skolnick M.H., Kamb A., and Wiseman R. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (1994) 120-122
39. Georgakilas A.G. A possible role of repair proteins BRCA1 and DNA-PK in the processing of oxidative DNA damage. J. Biochem. Tech. 1 (2008) 9-11
40. Georgakilas A.G. Processing of DNA damage clusters in human cells: current status of knowledge. Mol. Biosyst. 4 (2008) 30-35
41. Gollin S.M. Mechanisms leading to chromosomal instability. Semin. Cancer Biol. 15 (2005) 33-42
42. Guo G., Yan-Sanders Y., Lyn-Cook B.D., Wang T., Tamae D., Ogi J., Khaletskiy A., Li Z., Weydert C., Longmate J.A., Huang T.T., Spitz D.R., Oberley L.W., and Li J.J. Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol. Cell. Biol. 23 (2003) 2362-2378
43. Guo T.L., Chi R.P., Hernandez D.M., Auttachoat W., and Zheng J.F. Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein. Carcinogenesis 28 (2007) 2560-2566
44. Hada M., and Georgakilas A.G. Formation of clustered DNA damage after high-LET irradiation: a review. J. Radiat. Res. 49 (2008) 203-210
45. Hahn W.C., and Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 347 (2002) 1593-1603
46. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., and King M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (1990) 1684-1689
47. Hannah M.A., Siddiqui Y., Rostom A., Al-Ahdal M.N., Chaudhary M.A., and Kunhi M. Evidence of DNA repair/processing defects in cultured skin fibroblasts from breast cancer patients. Cancer Res. 61 (2001) 3627-3631
48. Hartman A.-R., and Ford J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 32 (2002) 180-184
49. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
50. Holt J.T., Thompson M.E., Szabo C., Robinson-Benion C., Arteaga C.L., King M.C., and Jensen R. Growth retardation and tumour inhibition by BRCA1. Nat. Genet. 12 (1996) 298-302
51. Hosey A.M., Gorski J.J., Murray M.M., Quinn J.E., Chung W.Y., Stewart G.E., James C.R., Farragher S.M., Mulligan J.M., Scott A.N., Dervan P.A., Johnston P.G., Couch F.J., Daly P.A., Kay E., McCann A., Mullan P.B., and Harkin D.P. Molecular basis for estrogen receptor {alpha} deficiency in BRCA1-linked breast cancer. J. Natl. Cancer Inst. 99 (2007) 1683-1694
52. Hussain S.P., Hofseth L.J., and Harris C.C. Radical causes of cancer. Nat. Rev. Cancer 3 (2003) 276-285
53. Jacinto F.V., and Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22 (2007) 247-253
54. Jeffy B.D., Chen E.J., Gudas J.M., and Romagnolo D.F. Disruption of cell cycle kinetics by benzo[a]pyrene: inverse expression patterns of BRCA-1 and p53 in MCF-7 cells arrested in S and G2. Neoplasia 2 (2000) 460-470
55. Jeffy B.D., Schultz E.U., Selmin O., Gudas J.M., Bowden G.T., and Romagnolo D. Inhibition of BRCA-1 expression by benzo[a]pyrene and its diol epoxide. Mol. Carcinogen. 26 (1999) 100-118
56. Joseph T., Kusumakumary P., Chacko P., Abraham A., and Pillai M.R. DNA repair gene XRCC1 polymorphisms in childhood acute lymphoblastic leukemia. Cancer Lett. 217 (2005) 17-24
57. Kanaar R., Hoeijmakers J.H., and van Gent D.C. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol. 8 (1998) 483-489
58. Kastan M.B., and Bartek J. Cell-cycle checkpoints and cancer. Nature 432 (2004) 316-323
59. Kim S.S., Cao L., Lim S.-C., Li C., Wang R.-H., Xu X., Bachelier R., and Deng C.-X. Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-{Delta}11 isoform. Mol. Cell. Biol. 26 (2006) 6983-6992
60. Kuschel B., Auranen A., McBride S., Novik K.L., Antoniou A., Lipscombe J.M., Day N.E., Easton D.F., Ponder B.A.J., Pharoah P.D.P., and Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 11 (2002) 1399-1407
61. Le Page F., Randrianarison V., Marot D., Cabannes J., Perricaudet M., Feunteun J., and Sarasin A. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxogunanine lesion in human cells. Cancer Res. 60 (2000) 5548-5552
62. Li L., Wang H., Yang E.S., Arteaga C.L., and Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 68 (2008) 9141-9146
63. Lindahl T., and Wood R.D. Quality control of DNA repair. Science 286 (1999) 1897-1905
64. Malins D.C., Polissar N.L., and Gunselman S.J. Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 2557-2563
65. Meek K., Gupta S., Ramsden D.A., and Lees-Miller S.P. The DNA-dependent protein kinase: the director at the end. Immunol. Rev. 200 (2004) 132-141
66. Meenakshhi N., Pai S.A., Shinde S.R., and Ghosh S.N. Reduced DNA repair capacity in breast cancer patients and unaffected individuals from breast cancer families. Cancer Genet. Cytogenet. 102 (1998) 65-73
67. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
68. Millikan R.C., Player J.S., de Cotret A.R., Tse C.K., and Keku T. Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk. Cancer Epidemiol. Biomark. 14 (2005) 2326-2334
69. Mitra A., Fisher C., Foster C.S., Jameson C., Barbachanno Y., Bartlett J., Bancroft E., Doherty R., Kote-Jarai Z., Peock S., Easton D., and Eeles R. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br. J. Cancer 98 (2008) 502-507
70. Moll U., Lau R., Sypes M.A., Gupta M.M., and Anderson C.W. DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene 18 (1999) 3114-3126
71. Morales J.C., Xia Z., Lu T., Aldrich M.B., Wang B., Rosales C., Kellems R.E., Hittelman W.N., Elledge S.J., and Carpenter P.B. Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability. J. Biol. Chem. 278 (2003) 14971-14977
72. Nephew K.P., and Huang T.M. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 190 (2003) 125-133
73. Nilsen H., and Krokan H.E. Base excision repair in a network of defense and tolerance. Carcinogenesis 22 (2001) 987-998
74. Nowsheen S., Wukovich R.L., Aziz K., Kalogerinis P.T., Richardson C.C., Panayiotidis M.I., Bonner W.M., Sedelnikova O.A., and Georgakilas A.G. Accumulation of oxidatively-induced clustered DNA lesions in human tumor tissues. Mutat. Res. 674 (2009) 131-136
75. Parchard R., Price F.M., Bohr V.A., Cowans K.H., Zujewski J.A., and Sanford K.K. Deficient DNA repair capacity, a predisposing factor in breast cancer. Br. J. Cancer 74 (1996) 1-5
76. Privat M., Aubel C., Arnould S., Communal Y., Ferrara M., and Bignon Y.-J. Breast cancer cell response to genistein is conditioned by BRCA1 mutations. Biochem. Biophys. Res. Commun. 379 (2009) 785-789
77. Pucci S., Mazzarelli P., Rabitti C., Giai M., Gallucci M., Flammia G., Alcini A., Altomare V., and Fazio V.M. Tumor specific modulation of Ku70/Ku80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene 20 (2001) 739-747
78. Puglisi F., Barbone F., Tell G., Aprile G., Pertoldi B., Raiti C., Kelley M.R., Damante G., Sobrero A., Beltrami C.A., and Di Loreto C. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol. Rep. 9 (2002) 11-17
79. Punnonen K., Ahotupa M., Asaishi K., Hyöty M., Kudo R., and Punnonen R. Antioxidant enzyme activities and oxidative stress in human breast cancer. J. Cancer Res. Clin. Oncol. 120 (1993) 374-377
80. Ramos J., Ruiz A., Colen R., Lopez I.D., Grossman L., and Matta J.L. DNA repair and breast carcinoma susceptibility in women. Cancer 100 (2004) 1352-1357
81. Rattenborg T., Gjermandsen I., and Bonefeld-Jorgensen E. Inhibition of E2-induced expression of BRCA1 by persistent organochlorines. Breast Cancer Res. 4 (2002) R12
82. Rattenborg T., Gjermandsen I., and Jorgensen E.C.B. Inhibition of E2-induced expression of BRCA1 by persistent organochlorines. Breast Cancer Res. (2002) 4
83. Rice J.C., Ozcelik H., Maxeiner P., Andrulis I., and Futscher B.W. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21 (2000) 1761-1765
84. Rodriguez H., Jaruga P., Leber R., Nyaga S.G., Evans M.K., and Dizdaroglu M. Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5′-cyclopurine-2′-deoxynucleosides and 8-hydroxy-2′-deoxyguanosine. Biochemistry 46 (2007) 2488-2496
85. Scully R., Ganesan S., Vlasakova K., Chen J., Socolovsky M., and Livingston D.M. Genetic analysis of BCA1 function in a defined tumor cell line. Mol. Cell 4 (1999) 1093-1099
86. Shrivastav M., De Haro L.P., and Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 18 (2008) 134-147
87. Smith R.A., Cokkinides V., and Brawley O.W. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA: Cancer J. Clin. 59 (2009) 27-41
88. Someya M., Sakata K., Matsumoto Y., Yamamoto H., Monobe M., Ikeda H., Ando K., Hosoi Y., Suzuki N., and Hareyama M. The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis 27 (2006) 117-122
89. Starcevic D., Dalal S., and Sweasy J.B. Is there a link between DNA polymerase beta and cancer?. Cell Cycle 3 (2004) 998-1001
90. Sweasy J.B., Lang T., Starcevic D., Sun K.W., Lai C.C., DiMaio D., and Dalal S. Expression of DNA polymerase beta cancer-associated variants in mouse cells results in cellular transformation. Proc. Natl. Acad. Sci. 102 (2005) 14350-14355
91. Tan D.S.P., Rothermundt C., Thomas K., Bancroft E., Eeles R., Shanley S., Ardern-Jones A., Norman A., Kaye S.B., and Gore M.E. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 26 (2008) 5530-5536
92. Thompson M.E., Jensen R.A., Obermiller P.S., Page D.L., and Holt J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9 (1995) 444-450
93. Treilleux S.A., Bremond A., Taniere P., and Hall J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology 43 (2003) 347-353
94. Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K., Steele D., Savage K., Gillett C.E., Schmitt F.C., Ashworth A., and Tutt A.N. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2006) 2126-2132
95. Tutt A.N.J., Lord C.J., McCabe N., Farmer H., Turner N., Martin N.M., Jackson S.P., Smith G.C., and Ashworth A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70 (2005) 139-148
96. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002) 171-182
97. Venkitaraman A.R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. Mech. Dis. 4 (2009) 461-487
98. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., and Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14 (2000) 927-939
99. Ward J.F. The complexity of DNA damage: relevance to biological consequences. Int. J. Radiat. Biol. 66 (1994) 427-432
100. Wei M., Grushko T.A., Dignam J., Hagos F., Nanda R., Sveen L., Xu J., Fackenthal J., Tretiakova M., Das S., and Olopade O.I. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 65 (2005) 10692-10699
101. Weiss J.M., Goode E.L., Ladiges W.C., and Ulrich C.M. Polymorphic variation in OGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol. Carcinogen. 42 (2005) 127-141
102. Welcsh P.L., and King M.-C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10 (2001) 705-713
103. Weydert C.J., Waugh T.A., Ritchie J.M., Lyer K.S., Smith J.L., Li L., Spitz D.R., and Oberley L.W. Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic. Biol. Med. 41 (2006) 226-237
104. Xia F., and Powell S.N. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin. Radiat. Oncol. 12 (2002) 296-304
105. Xu, X., Gammon, M., Zhang, Y., Bestor, T., Zeisel, S., Wetmur, J., Wallenstein, S., Bradshaw, P., Garbowski, G., Teitelbaum, S., Neugut, A., Santella, R., Chen, J., 2008. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res. Treat., doi:10.1007/s10549-008-0075-5.
106. Xu X., Wagner K.-U., Larson D., Weaver Z., Li C., Ried T., Hennighausen L., Wynshaw-Boris A., and Deng C.-X. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22 (1999) 37-43
107. Yoshikawa K., Honda K., Inamoto T., Shinohara H., Yamauchi A., Suga K., Okuyama T., Shimada T., Kodama H., Noguchi S., Gazdar A.F., Yamaoka Y., and Takahashi R. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res. 5 (1999) 1249-1261
108. Yu Y., Okayasu R., Weil M.M., Silver A., McCarthy M., Zabriskie R., Long S., Cox R., and Ullrich R.L. Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene. Cancer Res. 61 (2001) 1820-1824
109. Zhang Y., Carr T., Dimtchev A., Zaer N., Dritscilo A., and Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat. Res. 168 (2007) 115-124
110. Zhong Q., Chen C.F., Li S., Chen Y., Wang C.C., Xiao J., Chen P.L., Sharp Z.D., and Lee W.H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285 (1999) 747-750